ATS 2019 Virtual Final Program

P584 Prognostic Significance of Pneumothorax in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases/ K. Nishimoto, T. Fujisawa, K. Yoshimura, Y. Enomoto, H. Yasui, H. Hozumi, Y. Suzuki, M. Karayama, K. Furuhashi, N. Enomoto, Y. Nakamura, N. Inui, H. Sumikawa, T. Johkoh, T. Suda, Hamamatsu, Japan, p.A4756 CLINICAL THEMATIC POSTER SESSION C39 IDIOPATHIC INTERSTITIAL PNEUMONIA: THERAPY 9:15 a.m. - 4:15 p.m. KBHCCD Area H (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitators : R. Hallowell, MD, Boston, MA K. Tsushima, MD, PhD, Nagano, Japan P1084 Dyspnea Management in Interstitial Lung Disease: An Early Integrated Palliative Care Approach in a Multidisciplinary Setting/ L. van den Bosch, M. Kalluri, Edmonton, Canada, p.A4757 P1085 Characteristics of a Real-World Canadian Cohort of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone/ C. Ryerson, M.R.J. Kolb, G.P. Cox, S. Shapera, J.J. Swigris, C.D. Fell, M. O’Brien, M. Yang, C. Cabalteja, O. Moran Mendoza, Vancouver, Canada, p.A4758 P1086 Low Starting-Dosage Reduce the Early Termination of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis/ S. Ikeda, A. Sekine, T. Baba, T. Katano, G. Matama, N. Aiko, K. Isomoto, R. Otoshi, E. Tabata, R. Shintani, T. Niwa, T. Oda, R. Okuda, H. Kitamura, T. Ogura, Yokohama, Japan, p.A4759 P1087 Randomized Phase 2 Study of Nintedanib with or Without Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Who Experienced a Clinically Meaningful Decline in Forced Vital Capacity During Prior Pirfenidone Administration/ S. Ikeda, A. Sekine, T. Baba, T. Katano, E. Tabata, R. Shintani, H. Yamakawa, T. Oda, R. Okuda, H. Kitamura, T. Iwasawa, T. Takemura, T. Ogura, Yokohama, Japan, p.A4760 P1088 Medication Discontinuation and Survival in Elderly Veterans on Antifibrotics for Idiopathic Pulmonary Fibrosis/ J. Ryan, K. Malcolm, E.D. Farrand, N.A. Kolaitis, B.J. Ley, J.K. Brown, J.R. Greenland, San Francisco, CA, p.A4761 P1089 Analysis of Effectiveness of Pirfenidone in Subgroups of Idiopathic Pulmonary Fibrosis Based on Real World Data from European IPF Registry/ E. Krauss, F. Drakopanagiotakis, U. Costabel, M.A. Nieto Barbero, V. Mueller, P. Bonniaud, C. Vancheri, A.U. Wells, M. Vasakova, A. Pesci, W. Klepetko, W. Seeger, B. Crestani, A. Guenther, Giessen, Germany, p.A4762 P1090 Correlation Between Circulating Fibrocytes and Therapeutic Effects of Nintedanib/ H. Kobayashi, Suzuka, Japan, p.A4763 P1091 Early Permanent Discontinuation of Nintedanib Due to Adverse Events in Patients with IPF in a Real-Life Setting/ O. Nishiyama, R. Yamazaki, S. Saeki, A. Sano, H. Sano, T. Iwanaga, R. Haraguchi, H. Kume, Y. Tohda, Osakasayama, Japan, p.A4764 P1092 Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing Non-IPF Interstitial Lung Diseases/ S.E. Torrisi, N.C. Kahn, J. Waelscher, N. Sarmand, M. Polke, C.P. Heussel, S. Palmucci, G. Sambataro, C. Vancheri, M. Kreuter, Heidelberg, Germany, p.A4765 P1093 The Effect of Nintedanib on Clinical Outcome of 158 Patients with Idiopathic Pulmonary Fibrosis in Real World Settings/ M. Dobashi, H. Tanaka, K. Taima, M. Itoga, Y. Ishioka, K. Baba, T. Shiratori, F. Okumura, C. Tabe, Y. Tanaka, Y. Hasegawa, H. Yasugahira, K. Okudera, S. Takanashi, S. Tasaka, Hirosaki, Japan, p.A4766 P1094 Dual Antifibrotic Therapy for Fibrotic Lung Diseases in Clinical Practice/ G.A. Fernandez, N. Kazzaz, P. Rali, G.J. Criner, Philadelphia, PA, p.A4767 Facilitator : M.J. Hamblin, MD, Kansas City, KS P1095 Continuous Administration of Morphine for Terminal Interstitial Pneumonia Patients with or Without Cancer: A Single Center Retrospective Study/ H. Okabayashi, H. Kitamura, T. Harada, A. Yamaguchi, M. Horikoshi, K. Yamaguchi, H. Nakagawa, M. Asaoka, K. Isomoto, A. Sekine, T. Baba, S. Komatsu, E. Hagiwara, R. Matsuo, T. Ogura, Yokohama, Japan, p.A4768 P1096 Safety and Efficacy of Low-Dose Prednisolone with Pirfenidone in Idiopathic Pulmonary Fibrosis/ S. Matsubayashi, S. Izumi, H. Takumida, H. Watanabe, S. Matsumoto, Y. Kusaba, T. Katsuno, T. Kakuwa, Y. Tsujimoto, K. Sakamoto, M. Hashimoto, S. Ishii, E. Morino, M. Suzuki, J. Takasaki, G. Naka, M. Iikura, Y. Takeda, H. Sugiyama, Tokyo, Japan, p.A4769 P1097 Efficacy and Safety of Pirfenidone in Idiopathic Pulmonary Fibrosis According to Dose and Disease Severity/ J.S. Park, J.-K. Lee, S.M. Choi, J.Y. Cho, Y.J. Lee, Y.-J. Cho, J.-J. Yim, J. Lee, C.-T. Lee, Y.W. Kim, H. Hwang, Seongnam, Korea, Republic of, p.A4770 P1098 Supplemental Oxygen Use in Patients with Fibrotic Interstitial Lung Disease: An International Qualitative Study/ C.J. Humphreys, R. Lim, J. Morisset, A.E. Holland, K.A.M. Johannson, Calgary, Canada, p.A4771 P1099 Expression of GR- a and HDAC2 in Steroid-Sensitive and Steroid-Insensitive Interstitial Lung Disease/ Z. He, Y. Bin, L. Wu, Y. Liang, J. Bai, J. Zhang, M. Li, X. Zhong, Nanning, China, p.A4772 P1100 A Multicenter Study for the Evaluation of Effectiveness and Safety of Nintendanib in the Treatment of Idiopathic Pulmonary Fibrosis/ K. Antoniou, A. Trachalaki, S. Chrysovalantis, E. Vasarmidi, F. Bardaka, E. Bibaki, E. Fouka, G. Meletis, S. Trifon, Z. Daniil, D. Papakosta, Herakleion, Greece, p.A4773 P1101 Frequency of Lab Abnormalities in Patients Taking Mycophenolate or Azathioprine: A Retrospective Single Center Analysis/ A. Gopalan, A.M. Scott, T.M. Kohal, J.J. Dueweke, J.H. Jennings, K. Thavarajah, Detroit, MI, p.A4774 ATS 2019 • Dallas, TX TUESDAY • MAY 21 251 TUESDAY MORNING